Recent Updates
Recently added Catalysts
KRYS Positive Sentiment Score: 75/100

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

Key Takeaway: Krystal Biotech, Inc. will present at the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. CEO Krish S. Krishnan will participate in a fireside chat and host investor meetings. The event underscores the company's commitment to advancing genetic medicines, including its first product, VYJUVEK®, approved for dystrophic epidermolysis bullosa.

Market Sentiment Analysis

POSITIVE FACTORS

  • Krystal Biotech is actively engaging with investors at a major conference.
  • The company showcases its innovative gene therapy product, VYJUVEK®.
  • Participation in the BofA Securities conference highlights Krystal's growth.

Full Press Release Details

PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) --Krystal Biotech, Inc.(the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day.
A webcast of the presentation will be availableherebeginning at 11:20 am PT on Wednesday, May 13, 2026 and will be posted on the Investors section of the Company’swebsite.
About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visitwww.krystalbio.comto learn more or follow us onLinkedInandX.

CONTACTInvestors and Media:Stéphane Paquette, PhDKrystal Biotechspaquette@krystalbio.com

Frequently Asked Questions

When will Krystal Biotech present at the conference?

Krystal Biotech will present at the BofA Securities 2026 Health Care Conference on May 13, 2026.

Who will represent Krystal Biotech at the conference?

Krish S. Krishnan, the CEO, will represent Krystal Biotech during the event.

What is VYJUVEK®?

VYJUVEK® is Krystal Biotech's first commercial product, a gene therapy for dystrophic epidermolysis bullosa.

Where is Krystal Biotech headquartered?

Krystal Biotech is headquartered in Pittsburgh, Pennsylvania.

Last updated: May 7, 2026